Numerai’s ANI Pharmaceuticals ANIP Stock Holding History

Numerai’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,006	Closed	-$550K	–	618
2025 Q3	$550K	Buy	+6,006	New	+$490K	0.08%	318

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Numerai's ANIP Position: Q4 2025 in Review

Numerai sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 6,006 shares — an estimated $550K sold.

Numerai first reported a position in ANIP in Q3 2025 and held it in 1 quarter. The position peaked at $550K in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

Numerai reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Numerai sold 6,006 ANI Pharmaceuticals shares in Q4 2025, an estimated $550K.
Numerai first reported a position in ANI Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Numerai's ANI Pharmaceuticals position peaked at $550K in Q3 2025.
284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Numerai's 13F filing for Q4 2025, filed 17 Feb 2026.